• Explore /
  • Poster
  • / ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

Abstract Poster

Authors

null

Emeline Colomba

Gustave Roussy Cancerology Institute, Villejuif, Gineco Group, France

Emeline Colomba , Sarah Flora Jonas , Jean-Christophe Eymard , Remy Delva , Pierre-Emmanuel Brachet , Yann Neuzillet , Nicolas Penel , Guilhem Roubaud , Emmanuelle Bompas , Hakim Mahammedi , Raffaele Longo , Carole Helissey , Philippe Barthelemy , Delphine Borchiellini , Ali Hasbini , Franck Priou , Carolina Saldana , Eric Voog , Stéphanie Foulon , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03314324

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5046)

DOI

10.1200/JCO.2021.39.15_suppl.5046

Abstract #

5046

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Geraldine Martineau

First Author: Geraldine Martineau

First Author: Andrew Leonard Laccetti

First Author: Edwina S. Baskin-Bey